Summary
Global Markets Direct’s, ‘Acute Coronary Syndrome - Pipeline Review, H1 2016’, provides an overview of the Acute Coronary Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
- The report reviews pipeline therapeutics for Acute Coronary Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Coronary Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Acute Coronary Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
advanceCor GmbH
Arena Pharmaceuticals, Inc.
Artery Therapeutics, Inc.
Athera Biotechnologies AB
Bayer AG
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
CSL Limited
Esperion Therapeutics, Inc.
GlaxoSmithKline Plc
Japan Tobacco Inc.
Lee's Pharmaceutical Holdings Limited
MedImmune, LLC
Pfizer Inc.
The Medicines Company
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Coronary Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Coronary Syndrome - Overview 10
Acute Coronary Syndrome - Therapeutics under Development by Companies 11
Acute Coronary Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Acute Coronary Syndrome - Products under Development by Companies 15
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 16
advanceCor GmbH 16
Arena Pharmaceuticals, Inc. 17
Artery Therapeutics, Inc. 18
Athera Biotechnologies AB 19
Bayer AG 20
Cardiome Pharma Corp. 21
Cerenis Therapeutics Holding SA 22
CSL Limited 23
Esperion Therapeutics, Inc. 24
GlaxoSmithKline Plc 25
Japan Tobacco Inc. 26
Lee's Pharmaceutical Holdings Limited 27
MedImmune, LLC 28
Pfizer Inc. 29
The Medicines Company 30
Acute Coronary Syndrome - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
4-WF - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AEM-28 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AEM-2802 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Artpep-2 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Biologics for Acute Coronary Syndrome - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CER-001 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
COR-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
COR-3 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CSL-112 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
dalcetrapib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
losmapimod - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MDCO-216 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MEDI-6012 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PC-mAb - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PF-06282999 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PMC-6 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PR-15 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rivaroxaban - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
temanogrel hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
tirofiban hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ZK-001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Acute Coronary Syndrome - Recent Pipeline Updates 78
Acute Coronary Syndrome - Dormant Projects 100
Acute Coronary Syndrome - Discontinued Products 102
Acute Coronary Syndrome - Product Development Milestones 104
Featured News & Press Releases 104
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 104
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 105
Feb 23, 2016: Meta-Analysis of AGGRASTAT (Tirofiban HCl) Presented at CRT 2016 Conference 105
Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy 105
Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 107
Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study) 108
Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 108
Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 110
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 111
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114
List of Tables
Number of Products under Development for Acute Coronary Syndrome, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2016 16
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 17
Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H1 2016 18
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2016 19
Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2016 20
Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H1 2016 21
Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 22
Acute Coronary Syndrome - Pipeline by CSL Limited, H1 2016 23
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H1 2016 24
Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016 25
Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H1 2016 26
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 27
Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2016 28
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H1 2016 29
Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2016 30
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 78
Acute Coronary Syndrome - Dormant Projects, H1 2016 100
Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2016 101
Acute Coronary Syndrome - Discontinued Products, H1 2016 102
Acute Coronary Syndrome - Discontinued Products (Contd..1), H1 2016 103
List of Figures
Number of Products under Development for Acute Coronary Syndrome, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Top 10 Targets, H1 2016 32
Number of Products by Stage and Top 10 Targets, H1 2016 32
Number of Products by Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Top 10 Molecule Types, H1 2016 38
Number of Products by Stage and Top 10 Molecule Types, H1 2016 38
